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Abstract
In developing liposomes for in vivo use, it is important to design the liposomes to have optimal in vivo kinetics, and it is also
necessary to identify optimal high-throughput production conditions for these liposomes. Previous work has not definitively
established the general relationship between liposomes’ configuration and composition, and their in vivo kinetics. Also, no
straightforward method exists to calculate optimal liposome high-throughput production conditions for specific liposome
compositions. This work presents first-principles quantitative correlations describing liposomes’ in vivo drug leakage and
vascular mass transfer kinetics. This work further presents a simple quantitative model relating specific liposome
compositions to ideal high-throughput production parameters. The results have implications for the identification of
promising liposome compositions via high-throughput screening methodologies, as well as the design and optimization of
high-throughput reactors for liposome production.
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Introduction
Many drugs are attendant with significant systemic risks and
side effects. To allow these drugs to achieve the treatment ideality
of maximal efficacy and maximal specificity, it is necessary to use a
targeted drug carrier to deliver and release the drugs specifically at
the right time and at the right location [1].
Closed phospholipid vesicles (i.e., liposomes) are widely used as
targeted drug carriers to deliver and release drugs in appropriate
amounts at specific times and specific locations in the body.
Existing liposomes exhibit undesirable in vivo characteristics
including intrinsic destabilization, drug leakage, immunogenicity,
and short plasma half-life [2]. Hence, research toward developing
better liposomes is of significant importance.
Liposomes with optimal in vivo characteristics can be developed
with knowledge of potential liposome compositions’ in vivo kinetics.
The in vivo kinetics of some liposome compositions have been
characterized by experimental studies [3]. However, for rapid high-
throughput screening of potential liposome compositions, it would
be ideal to have broadly valid correlations allowing the prediction of
liposomes’ in vivo kinetics for many different liposome compositions.
Also, it is important to identify optimal high-throughput
industrial liposome production conditions for liposome composi-
tions of interest. While efficient industrial production conditions
have been experimentally identified (mostly through trial and
error) for some liposome compositions [3], it would be ideal to
have a broadly valid quantitative model allowing the prediction of
optimal production conditions for many different liposome
compositions.
This work presents generally valid quantitative models describ-
ing liposomes’ high-throughput production and predicting lipo-
somes’ in vivo drug leakage and vascular mass transfer kinetics for
many liposome compositions.
Results
Encapsulated drug leakage from multilamellar liposome
vesicles (MLVs)
Drug leakage from a widely used type of liposome, multi-
lamellar liposomes (MLVs), is inherently minimized relative to
drug leakage from one-layer, or unilamellar, liposomes due to
MLVs’ basic configuration (Figure 1 – artist’s rendition of a cross
section of a spherically symmetric, homogeneous, drug-encapsu-
lating MLV). Via the general species conservation equation [4],
drug leakage over time from a spherically symmetric, homoge-
neous, drug-encapsulating MLV can be described by the following
series:
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C0=initial (immediate post-loading) concentration of the drug
in the MLV
D=diffusivity of the drug in the MLV
kC=mass transfer coefficient of the drug
R=radius of the MLV
t=elapsed time
Here, the term ‘‘homogeneous’’ is used to refer to the drug
particles being evenly mixed with the lipid molecules throughout
the MLV.
Vascular mass transfer
A critically important issue associated with using liposomes in
biological systems is the question of how the liposomes migrate in
the bloodstream (Figure 2). From the general linear momentum
conservation equation [4]–[6], the mass transfer of liposomes (of
any type) in a blood vessel as a function of axial position can be
described as:
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Cb=bulk liposome concentration in a vessel
Co=initial (inlet) liposome concentration
kc=mass transfer coefficient of the liposomes in the bloodstream
km=mass transfer coefficient of the liposomes in the vessel wall
kt=mass transfer coefficient of the liposomes in the tissue space
=dynamic pressure in the vessel
R=radius of the blood vessel
m=dynamic viscosity of the blood
U=mean velocity of fluid flow in the vessel
High-throughput continuous tubular reactor (CTR)
production rate
A highly efficient method for producing large quantities of drug-
encapsulating liposomes rapidly comprises using a continuous flow
reactor that can be run indefinitely as long as adequate quantities
of reagents are supplied [7]. For these CTRs, a mole balance
equation [8] can be used to develop a set of differential equations
governing the liposome synthesis reaction. For example, for drug-
encapsulating liposomes with targeting moieties (e.g., liposome-
surface receptors), the synthesis reaction can be represented as
follows, based on experimental measurements [9]–[11] of typical
numbers of targeting moieties/receptors, drug particles, and lipid
molecules per liposome (Figure 3):
100 Targeting Receptors (TR) (l)z10000 Drug (DRG) (l)z
80000 Lipid (LIP) (s)?Liposome (DEL) (l)
Assuming pseudo-second order kinetics with a large excess of lipid
(LIP) [9]–[11], the governing differential equations are:
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where:
d=CTR diameter
k=reaction rate coefficient
u=feed flow rate in the CTR
Discussion
This work presents first principles quantitative correlations
characterizing the core rate processes associated with the high-
throughput production and in vivo kinetics of (drug-encapsulating)
Figure 1. Encapsulated drug leakage from a MLV (schematic). A
homogeneous, spherically symmetric, drug-encapsulating MLV.
doi:10.1371/journal.pone.0010280.g001
Figure 2. Vascular mass transfer of liposomes (schematic).
Migration of liposomes in a blood vessel. Applicable mass transfer
coefficients are shown.
doi:10.1371/journal.pone.0010280.g002
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lated drug leakage kinetics, vascular mass transfer kinetics and
high-throughput production kinetics.
The models can be used to facilitate the high-throughput
screening of drug-encapsulating liposome compositions, configu-
rations, and/or synthesis methods, with modeling data output
employed as a preliminary rapid and low-cost filter in evaluating
many different drug-encapsulating liposome compositions, config-
urations, and synthesis procedures. For example, the models could
be used to screen different drugs to see which drugs, based on
known biophysical properties, could potentially be carried and
delivered effectively by a MLV. Also, the models could be used to
screen different lipid modifications to see what kinds of
modifications (based on known biophysical properties) might
minimize undesired leakage of a particular drug. Other applica-
tions are also possible.
Compositions, configurations, or synthesis methods deemed to
be promising based on the modeling output could then be
further tested and characterized experimentally. Such a
screening methodology is particularly important because past
efforts to identify effective novel compositions, configurations, or
synthesis methods have been limited due to an almost exclusive
reliance on direct experimental testing. High-throughput screen-
ing using these models hence provides a way to test many more
compositions, configurations, and synthesis methods (and
identify more promising candidates) than experimental testing
alone.
Further work may be performed to test and adapt these
models for specific experimental conditions in practice. Also,
future studies could extend these models to cover additional
classes of liposomes and to other biologically relevant micro- and
nanoparticles.
Methods
Species conservation
LCi
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Where:
Ci=molar concentration of species i
Ni=molar flux of species i (using fixed coordinates)
Ri=net rate of formation of species i per unit volume
Assume i is a minor component in a pseudobinary, constant
density, constant diffusivity liquid solution. Then:
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For a spherically symmetric, homogeneous drug-encapsulating
MLV:
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Where:
C=concentration of the drug within the MLV
D=diffusivity of the drug within the MLV
t=elapsed time
Figure 3. Production of liposomes in a CTR. Predicted concentrations of reagents and drug-encapsulating liposomes as a function of reactor
position. Initial conditions used: [TR]=500 arbitrary units (a.u.); [DRG]=50000 a.u.; [DEL]=0 a.u.
doi:10.1371/journal.pone.0010280.g003
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kC=mass transfer coefficient of the drug within the MLV
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Linear momentum conservation
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For a constant viscosity, constant density, incompressible Newto-
nian fluid:
r
Dv
Dt
~rg{+Pzm+2v
Or:
r
Dv
Dt
~{+ zm+2v
Where:
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Assume fully developed unidirectional flow. Then:
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Per species conservation:
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Where:
C=liposome concentration within the vessel
Integrate over r:
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Apply the following correlations:
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Where:
Ct=liposome concentration in the tissue at the surface of the
outer vessel wall
Then:
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CTR mole balance
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Assume low feed flow rate. Then:
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Where:
Cj=concentration of species j
L=position in reactor
u=feed flow rate
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Where:
A=area of reactor
d=diameter of reactor
Nj=number of moles of species j
r=radius of reactor
V=volume of reactor
Assume pseudo-second order kinetics with large excess of
deposited lipid. Use:
100 Targeting Receptors (TR) (l)+10000 Drug (DRG) (l)+80000
Lipid (LIP) (s)RLiposome (DEL) (l)
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Where:
d=CTR diameter
k=reaction rate coefficient
u=feed flow rate in the CTR
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